[{"orgOrder":0,"company":"Ab Initio Pharma","sponsor":"ResolutionRx","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Sleep","graph2":"Phase II","graph3":"Ab Initio Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ab Initio Pharma \/ ResolutionRx","highestDevelopmentStatusID":"8","companyTruncated":"Ab Initio Pharma \/ ResolutionRx"}]

Find Clinical Drug Pipeline Developments & Deals by Ab Initio Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Iran Expo
                          Not Confirmed
                          Iran Expo
                          Not Confirmed

                          Details : The initial services relate to ResolutionRx’s repurposing of dronabinol and its development program for obstructive sleep apnea pursuant to which Ab Initio will, among other things, manufacture and test the new dronabinol lipid nanoparticle formulation...

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          December 10, 2023

                          Lead Product(s) : Tetrahydrocannabinol

                          Therapeutic Area : Sleep

                          Highest Development Status : Phase II

                          Sponsor : ResolutionRx

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank